Acceptability of a Fixed Combination of Fenofibrate and Metformin
Phase 3
Completed
- Conditions
- Dyslipidemia/Glucose Metabolism Disorder
- Registration Number
- NCT00348725
- Lead Sponsor
- Solvay Pharmaceuticals
- Brief Summary
The primary objective was to assess the acceptability of a 4-week treatment of 4 new fixed-dose combinations of fenofibrate and metformin, in patients with type 2 diabetes and dyslipidemia.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 69
Inclusion Criteria
- Patients with type 2 diabetes mellitus and dyslipidemia.
Exclusion Criteria
- Type 1 diabetes, uncontrolled type 2 diabetes, - HbA1c ≥ 10 % - Fasting plasma glucose > 300 mg/dL - Triglycerides > 500 mg/dL
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Quotation by Visual Numeric Rating Scale before and after 4-week treatment
- Secondary Outcome Measures
Name Time Method Assessment of safety by reporting of Adverse Events
Trial Locations
- Locations (25)
Site 24
🇫🇷Anzin, France
Site 23
🇫🇷Bachant, France
Site 21
🇫🇷Baune, France
Site 32
🇫🇷Bersee, France
Site 34
🇫🇷Briollay, France
Site 27
🇫🇷Denain, France
Site 28
🇫🇷Denain, France
Site 5
🇫🇷Le Temple de Bretagne, France
Site 29
🇫🇷Nantes, France
Site 2
🇫🇷Nantes, France
Scroll for more (15 remaining)Site 24🇫🇷Anzin, France